Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems.
about
A nationwide analysis of incidence and outcome of breast cancer in the country of Surinam, during 1994-2003.Molecular mechanisms of antigen retrieval: antigen retrieval reverses steric interference caused by formalin-induced cross-links.Prognostic and predictive value of low estrogen receptor expression in breast cancerDiscordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?CD147 expression in human gastric cancer is associated with tumor recurrence and prognosis.High level of microtubule-associated protein light chain 3 predicts poor prognosis in resectable esophageal squamous cell carcinoma.Hormone receptor and ERBB2 status in gene expression profiles of human breast tumor samplesExpression of the phosphorylated MEK5 protein is associated with TNM staging of colorectal cancer.When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry--the red, brown, and blue technique.Technical note on the validation of a semi-automated image analysis software application for estrogen and progesterone receptor detection in breast cancer.B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells.A roundtable discussion of aromatase inhibitors as therapy for breast cancer.Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinomaObserver accuracy in estimating proportions in images: implications for the semiquantitative assessment of staining reactions and a proposal for a new systemEstrogen and HER-2 receptor discordance between primary breast cancer and metastasis.The effect of fixation and processing on the sensitivity of oestrogen receptor assay by immunohistochemistry in breast carcinomaHighly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients.The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast.NDRG4, a novel candidate tumor suppressor, is a predictor of overall survival of colorectal cancer patients.Quantification of Estrogen Receptor-Alpha Expression in Human Breast Carcinomas With a Miniaturized, Low-Cost Digital Microscope: A Comparison with a High-End Whole Slide-ScannerTesting for HER2 in breast cancer.Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme.Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program.An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens.Gene signatures in breast cancer: current and future uses.Practical implications of gene-expression-based assays for breast oncologists.A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.In situ Protein Detection for Companion Diagnostics.The analytical validation of the Oncotype DX Recurrence Score assayDoes confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?Surgical oophorectomy for breast cancer: back to the future.Analytic variability in immunohistochemistry biomarker studies.The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.Study assessing the quality of quantification of estrogen receptor protein expression by immunohistochemistry and gene expression in breast cancer.High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.
P2860
Q29353827-A104A4B5-73D6-4FF3-8E8C-55C9CF98D000Q30382246-21770B06-027E-48C2-9E9C-65F202BC3014Q33611133-DF89D5BC-56E6-479A-A059-421668DBA747Q33699614-5927B2E0-7270-47DB-969D-1C8046DE96F6Q33825595-F4B46CD2-5431-4F03-99E8-76835DAC45A2Q34029203-4C1CBC17-4F1A-4AF7-BED2-7850640DCC14Q34055901-92516282-3860-4B6B-9D74-7AEF3F977BFBQ34212935-1C9CD766-67C8-494D-AF65-7C424136D3F2Q34377983-0BDDAED3-20AE-41E3-9BC4-3C2CDEEA8DDAQ34540794-45496DC3-C78B-4457-A784-8E007535FB45Q35016870-44D8D99C-3838-421B-A400-56E6F0EB618BQ35129669-FE1A37C4-92D3-4EEC-9D0A-B85ED57DA245Q35396049-E989F58B-A1B3-401F-BBFF-FEDBD850AA24Q35396974-F094D52C-6AB2-4D63-8117-0ED3FCEA7166Q35397963-50532106-E919-4E6C-94F7-A3E6B589723FQ35398756-A5D62C60-4E47-45A6-98C9-E83739EEB616Q35583809-9141D28A-8356-4559-A108-35411A92DA5DQ35586038-D4E86535-A525-46C3-8775-B75420E79A42Q35735913-16476FED-3566-4CBF-B949-87745562722DQ35770497-7CD58547-417F-4F01-8D75-1E49BA815864Q35781352-F5A11294-5AE4-44B6-B812-FA5511BBFB8CQ35867253-7414C32D-3023-4CF8-BE27-87F59112900CQ35871999-7FB7BF3A-0251-47C5-8A9F-84FAA5527E19Q35909719-794943C2-4753-4730-BE36-ECF61AB838B5Q36017256-C1F55A0A-43BB-43ED-BD33-A8228583A7A7Q36172181-F67D61EF-A8C5-46C4-8085-012C6E078CFDQ36172499-C1094FD5-8CB4-43BA-8974-39B9690A7DD0Q36525765-3BE35EC0-D58A-400F-8C5F-EF9A5DFD4A95Q36989546-7DD03CD1-BE9E-4B82-A424-91FC4FC01936Q37095809-7157A3B3-74EA-41AD-BA8C-95A9B64F7E3CQ37155629-C48CFF5B-C82E-44AA-9AB6-5FC30E8FA43AQ37249243-5E11660B-B9A8-4481-BC29-EC78BC24FFAAQ37270405-D66F5225-A59F-4A11-B864-1248148F290CQ37301556-62A2C0B8-E531-4A82-B19E-367B4705A16FQ37316222-F595A205-C9C4-43D7-B8DE-35F0C4535D28Q37351996-679D9A83-A0B0-48C5-9FA8-D9FA912F4102Q37479225-B03E0EC3-EC09-4D67-B70E-E5B69AFD1219Q37564425-3B4FADF4-B019-4EFD-AE1D-6FEF2CC19CB9Q37661545-BA94723C-D6DF-48CD-AEBE-E1A32E2060A0Q37671966-A1ABE690-C5A4-4254-898C-D09B868AE8B2
P2860
Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Reliability of immunohistochem ...... evaluation of scoring systems.
@ast
Reliability of immunohistochem ...... evaluation of scoring systems.
@en
type
label
Reliability of immunohistochem ...... evaluation of scoring systems.
@ast
Reliability of immunohistochem ...... evaluation of scoring systems.
@en
prefLabel
Reliability of immunohistochem ...... evaluation of scoring systems.
@ast
Reliability of immunohistochem ...... evaluation of scoring systems.
@en
P2093
P2860
P356
P1476
Reliability of immunohistochem ...... evaluation of scoring systems.
@en
P2093
P2860
P304
P356
10.1136/JCP.53.2.125
P407
P577
2000-02-01T00:00:00Z